Effects of increasing cannabis potency on adolescent health

The Lancet Child and Adolescent Health

Volumn 3, Issue 2, 2019, Pages 121-128

  Wilson, Jack ^a   Freeman, Tom P ^a,b   Mackie, Clare J ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b University of Bath   (United Kingdom)

^c BETHLEM ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL;

ADOLESCENT; ADOLESCENT HEALTH; AGE; CANNABIS ADDICTION; COGNITIVE DEFECT; CONCENTRATION (PARAMETER); DISEASE SEVERITY; HEALTH CARE POLICY; HUMAN; PSYCHOSIS; RECALL; REVIEW; RISK ASSESSMENT; SPATIAL MEMORY; WORKING MEMORY; CANNABIS USE; CHEMISTRY; EPIDEMIOLOGY;

ADOLESCENT; ADOLESCENT HEALTH; CANNABIDIOL; CANNABIS; HUMANS; MARIJUANA USE;

EID: 85060125524     PISSN: None     EISSN: 23524642     Source Type: Journal    
DOI: 10.1016/S2352-4642(18)30342-0     Document Type: Review

References (68)

1. United Nations Office on Drugs and Crime. World Drug Report 2015. 2015, United Nations publication, Vienna.
2. Johnston, LD, O'Malley, PM, Miech, RA, Bachman, JG, Schulenberg, JE, Monitoring the Future national survey results on drug use, 1975–2016: overview, key findings on adolescent drug use. 2017, Institute for Social Research, The University of Michigan, Ann Arbor.
3. Degenhardt, L, Ferrari, AJ, Calabria, B, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLOS One, 8, 2013, e76635.
4. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2017: trends and developments. 2017, Publications Office of the European Union, Luxembourg.
5. Montanari, L, Guarita, B, Mounteney, J, Zipfel, N, Simon, R, Cannabis use among people entering drug treatment in Europe: a growing phenomenon?. Eur Addict Res 23 (2017), 113–121.
6. Freeman, TP, van der Pol, P, Kuijpers, W, et al. Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychol Med 48 (2018), 2346–2352.
7. ElSohly, MA, Mehmedic, Z, Foster, S, Gon, C, Chandra, S, Church, JC, Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psych 79 (2016), 613–619.
8. Smart, R, Caulkins, JP, Kilmer, B, Davenport, S, Midgette, G, Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 112 (2017), 2167–2177.
9. Sawyer, SM, Azzopardi, PS, Wickremarathne, D, Patton, GC, The age of adolescence. Lancet Child Adolesc Health 2 (2018), 223–228.
10. Chadwick, B, Miller, ML, Hurd, YL, Cannabis use during adolescent development: susceptibility to psychiatric illness. Front Psychiatry, 4, 2013, 129.
11. Curran, HV, Freeman, TP, Mokrysz, C, Lewis, DA, Morgan, CJA, Parsons, LH, Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 17 (2016), 293–306.
12. Keimpema, E, Mackie, K, Harkany, T, Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci 32 (2011), 551–561.
13. D'Souza, DC, Perry, E, MacDougall, L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (2004), 1558–1572.
14. Englund, A, Morrison, PD, Nottage, J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27 (2013), 19–27.
15. Morgan, CJA, Gardener, C, Schafer, G, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 42 (2012), 391–400.
16. Potter, DJ, A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal 6 (2013), 31–38.
17. Potter, DJ, Hammond, K, Tuffnell, S, Walker, C, Di Forti, M, Potency of Δ9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology. Drug Test Anal 10 (2018), 628–635.
18. Raber, JC, Elzinga, S, Kaplan, C, Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci 40 (2015), 797–803.
19. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2016: trends and developments. 2016, Publications Office of the European Union, Luxembourg http://www.emcdda.europa.eu/publications/edr/trends-developments/2016_en. (Accessed 30 November 2018)
20. Castaneto, MS, Gorelick, DA, Desrosiers, NA, Hartman, RL, Pirard, S, Huestis, MA, Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144 (2014), 12–41.
21. Trecki, J, Gerona, RR, Schwartz, MD, Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373 (2015), 103–107.
22. Swift, W, Wong, A, Li, KM, Arnold, JC, McGregor, IS, Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One, 8, 2013, e70052.
23. Niesink, RJ, Rigter, S, Koeter, MW, Brunt, TM, Potency trends of delta9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15. Addiction 110 (2015), 1941–1950.
24. Cascini, F, Aiello, C, Di Tanna, G, Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5 (2012), 32–40.
25. King, LA, Carpentier, C, Griffiths, P, EMCDDA insights—an overview of cannabis potency in Europe. 2015, Office for Official Publications of the European Communities, Luxembourg.
26. Caulkins, JP, Bao, Y, Davenport, S, et al. Big data on a big new market: insights from Washington State's legal cannabis market. Int J Drug Policy 57 (2018), 86–94.
27. Casey, BJ, Jones, RM, Hare, TA, The adolescent brain. Ann NY Acad Sci 1124 (2008), 111–126.
28. de Wit, H, Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 14 (2009), 22–31.
29. Logan, GD, Cowan, WB, Davis, KA, On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform 10 (1984), 276–291.
30. Verbuggen, F, Logan, GD, Response inhibition in the stop-signal paradigm. Trends Cogn Sci 12 (2008), 418–424.
31. Behan, B, Connolly, CG, Datwani, S, et al. Response inhibition and elevated parietal-cerebellar correlations in chronic adolescent cannabis users. Neuropharmacology 84 (2014), 131–137.
32. Norman, AL, Pulido, C, Squeglia, LM, Spadoni, AD, Paulus, MP, Tapert, SF, Neural activation during inhibition predicts initiation of substance use in adolescence. Drug Alcohol Depend 119 (2011), 216–223.
33. Mahmood, OM, Goldenberg, D, Thayer, R, Migliorini, R, Simmons, AN, Tapert, SF, Adolescents' fMRI activation to a response inhibition task predicts future substance use. Addict Behav 38 (2013), 1435–1441.
34. Tapert, SF, Schweinsburg, AD, Drummond, SPA, et al. Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology 194 (2007), 173–183.
35. Drummond, SP, Bischoff-Grethe, A, Dinges, DF, Ayalon, L, Mednick, SC, Meloy, MJ, The neural basis of the psychomotor vigilance task. Sleep 28 (2005), 1059–1068.
36. Lopez-Larson, MP, Bogorodzki, P, Rogowska, J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res 220 (2011), 164–172.
37. Henquet, C, Di Forti, M, Morrison, P, Kuepper, R, Murray, RM, Gene-environment interplay between cannabis and psychosis. Schizophr Bull 34 (2008), 1111–1121.
38. Freeman, TP, Morgan, CJA, Hindocha, C, Schafer, G, Das, RK, Curran, HV, Just say ‘know’: how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?. Addiction 109 (2014), 1686–1694.
39. Korf, DJ, Benschop, A, Wouters, M, Differential responses to cannabis potency: a typology of users based on self-reported consumption behaviour. Int J Drug Policy 18 (2007), 168–176.
40. Large, M, Sharma, S, Compton, MT, Slade, T, Nielssen, O, Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 68 (2011), 555–561.
41. Mackie, CJ, O'Leary-Barrett, M, Al-Khudhairy, N, et al. Adolescent bullying, cannabis use and emerging psychotic experiences: a longitudinal general population study. Psychol Med 43 (2012), 1033–1044.
42. Mackie, CJ, Castellanos-Ryan, N, Conrod, PJ, Developmental trajectories of psychotic-like experiences across adolescence: impact of victimization and substance use. Psychol Med 41 (2010), 47–58.
43. Kuepper, R, van Os, J, Lieb, R, Wittchen, H-U, Höfler, M, Henquet, C, Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ, 342, 2011, d738.
44. Henquet, C, Krabbendam, L, Spauwen, J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ, 330, 2004, 11.
45. Di Forti, M, Marconi, A, Carra, E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2 (2015), 233–238.
46. Medina, KL, Hanson, KL, Schweinsburg, AD, Cohen-Zion, M, Nagel, BJ, Tapert, SF, Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc 13 (2007), 807–820.
47. Lisdahl, KM, Price, JS, Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. J Int Neuropsychol Soc 18 (2012), 678–688.
48. Alexandre, CJ, Waldo, ZA, Rocio, MS, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 24 (2009), 515–523.
49. Lev-Ran, S, Roerecke, M, Le Foll, B, George, TP, McKenzie, K, Rehm, J, The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 44 (2013), 797–810.
50. Gonzalez, R, Pacheco-Colón, I, Duperrouzel, JC, Hawes, SW, Does cannabis use cause declines in neuropsychological functioning? A review of longitudinal studies. J Int Neuropsychol Soc 23 (2017), 893–902.
51. Schoeler, T, Petros, N, Di Forti, M, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry 3 (2016), 947–953.
52. Chan, GCK, Hall, W, Freeman, TP, Ferris, J, Kelly, AB, Winstock, A, User characteristics and effect profile of butane hash oil: an extremely high-potency cannabis concentrate. Drug Alcohol Depend 178 (2017), 32–38.
53. Freeman, TP, Winstock, AR, Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 45 (2015), 3181–3189.
54. van der Pol, P, Liebregts, N, Brunt, T, et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 109 (2014), 1101–1109.
55. Mokrysz, C, Freeman, TP, Korkki, S, Griffiths, K, Curran, HV, Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Transl Psychiatry, 6, 2016, e961.
56. Pijlman, FTA, Rigter, SM, Hoek, J, Goldschmidt, HMJ, Niesink, RJM, Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biology 10 (2006), 171–180.
57. Gage, SH, Hickman, M, Heron, J, et al. Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. Psychol Med 44 (2014), 3435–3444.
58. Hindocha, C, Norberg, MM, Tomko, RL, Solving the problem of cannabis quantification. Lancet Psychiatry, 5, 2018, e8.
59. Murray, RM, Quigley, H, Quattrone, D, Englund, A, Di Forti, M, Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry 15 (2016), 195–204.
60. Yücel, M, Lorenzetti, V, Suo, C, et al. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry, 6, 2016, e710.
61. Demirakca, T, Sartorius, A, Ende, G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 114 (2011), 242–245.
62. Subbaraman, MS, Substitution and complementarity of alcohol and cannabis: a review of the literature. Subst Use Misuse 51 (2016), 1399–1414.
63. Degenhardt, L, Stockings, E, Patton, G, Hall, WD, Lynskey, M, The increasing global health priority of substance use in young people. Lancet Psychiatry 3 (2016), 251–264.
64. Salloum, NC, Krauss, MJ, Agrawal, A, Bierut, LJ, Grucza, RA, A reciprocal effects analysis of cannabis use and perceptions of risk. Addiction 113 (2018), 1077–1085.
65. Foxcroft, D R, Tsertsvadze, A, Universal school-based prevention programs for alcohol misuse in young people. Cochrane Database Syst Rev, 5, 2011 CD009113.
66. Faggiano, F, Silvia, M, Versino, E, Daria, B, Universal school-based prevention for illicit drug use. Cochrane Database Syst Rev, 12, 2014 CD003020.
67. Newton, NC, Andrews, G, Teesson, M, Vogl, LE, Delivering prevention for alcohol and cannabis using the internet: a cluster randomised controlled trial. Prev Med 48 (2009), 579–584.
68. Freeman, TP, Wilson, J, Mackie, C, Commentary on Salloum et al. (2018): rethinking adolescent cannabis use and risk perception. Addiction 113 (2018), 1086–1087.